Sign In
Buy CLLS
$3.09
-0.290 (-8.58%)
At Close: Jun 03, 2026
Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)
10:37am, Wednesday, 10'th Jul 2024
Cellectis (CLLS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
04:30pm, Friday, 28'th Jun 2024
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving c
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
04:30pm, Thursday, 20'th Jun 2024
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform t
Cellectis (CLLS) Upgraded to Buy: Here's Why
01:01pm, Tuesday, 18'th Jun 2024
Cellectis (CLLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)
10:35am, Tuesday, 18'th Jun 2024
The heavy selling pressure might have exhausted for Cellectis (CLLS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
04:30pm, Wednesday, 12'th Jun 2024
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
04:30pm, Tuesday, 04'th Jun 2024
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform t
Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript
02:06pm, Thursday, 30'th May 2024
Cellectis S.A. (NASDAQ:CLLS ) Q1 2024 Earnings Conference Call May 29, 2024 8:00 AM ET Company Participants Arthur Stril - Interim-CFO André Choulika - CEO Mark Frattini - Chief Medical Officer Confe
Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024
09:14am, Thursday, 30'th May 2024
Data update from phase 1 BALLI-01 study, using UCART22 for the treatment of B-cell acute lymphoblastic leukemia, expected by the end of 2024. The global acute lymphoblastic leukemia therapeutics marke
Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024
04:30pm, Wednesday, 29'th May 2024
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to de
Cellectis Reports Financial Results for First Quarter 2024
04:30pm, Tuesday, 28'th May 2024
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 2024 1 ; cash runway projection into 2026 2 •
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
04:30pm, Monday, 27'th May 2024
NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to de
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
02:00am, Monday, 06'th May 2024
Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
04:30pm, Thursday, 02'nd May 2024
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
04:46pm, Monday, 29'th Apr 2024
• Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting
